- Home
- GYRE vs PEB Comparison
GYRE vs PEB Comparison
Compare GYRE & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- PEB
- Stock Information
- Founded
- GYRE 2002
- PEB 2009
- Country
- GYRE United States
- PEB United States
- Employees
- GYRE N/A
- PEB N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- GYRE Health Care
- PEB Real Estate
- Exchange
- GYRE Nasdaq
- PEB Nasdaq
- Market Cap
- GYRE 897.1M
- PEB 1.1B
- IPO Year
- GYRE N/A
- PEB 2009
- Fundamental
- Price
- GYRE $7.57
- PEB $10.78
- Analyst Decision
- GYRE
- PEB Hold
- Analyst Count
- GYRE 0
- PEB 7
- Target Price
- GYRE N/A
- PEB $11.71
- AVG Volume (30 Days)
- GYRE 159.6K
- PEB 2.2M
- Earning Date
- GYRE 08-12-2025
- PEB 07-29-2025
- Dividend Yield
- GYRE N/A
- PEB 0.37%
- EPS Growth
- GYRE N/A
- PEB N/A
- EPS
- GYRE 0.02
- PEB N/A
- Revenue
- GYRE $100,643,000.00
- PEB $1,459,506,000.00
- Revenue This Year
- GYRE $21.04
- PEB $1.63
- Revenue Next Year
- GYRE $89.64
- PEB $2.91
- P/E Ratio
- GYRE $95.15
- PEB N/A
- Revenue Growth
- GYRE N/A
- PEB 2.19
- 52 Week Low
- GYRE $6.11
- PEB $7.42
- 52 Week High
- GYRE $19.00
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- GYRE 47.42
- PEB 60.42
- Support Level
- GYRE $7.09
- PEB $10.30
- Resistance Level
- GYRE $7.63
- PEB $11.14
- Average True Range (ATR)
- GYRE 0.40
- PEB 0.35
- MACD
- GYRE 0.03
- PEB -0.03
- Stochastic Oscillator
- GYRE 42.74
- PEB 54.41
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.